Open-House original discount contracts for Roxadustat 2026-12

Summary

The tender concerns Open-House original discount contracts for Roxadustat. Participating health insurers aim to conclude discount agreements with all suitable pharmaceutical companies under uniform terms for the Roxadustat active substance. The contracts have a maximum duration of 24 months, starting 01 November 2026 and ending 31 October 2028; joining is open and no exclusivity is granted. The detailed conditions, pricing and other requirements will be defined in the tender documents.